Supernus, Indivior merge to beef up brain drug portfolio
Supernus, Indivior merge to beef up brain drug portfolio
Supernus Pharmaceuticals
Public biopharma (Nasdaq: SUPN) developing and commercializing CNS therapeutics across epilepsy, migraine, Parkinson's disease, ADHD and postpartum depression; agreed to an all-stock merger with Indivior in 2026.
Company Info
Upcoming Milestones & Key Dates
Q4 2026
Corporate
Expected close of all-stock merger with Indivior
Clinical Development Pipeline
Qelbree (viloxazine)
Target: SNRIZurzuvae (zuranolone)
Target: GABA-A receptor modulatorOnapgo (apomorphine)
Target: Dopamine agonistRecent News
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company
Supernus Pharmaceuticals and Indivior will merge to form a new CNS-focused pharmaceutical company.
Leadership Team
Jack Khattar
President and Chief Executive Officer